000			02034 a2200565 4500
005			20250515192113.0
264		0	_c20100223
008			201002s 0 0 eng d
022			_a1528-0020
024	7		_a10.1182/blood-2009-08-237727 _2doi
040			_aNLM _beng _cNLM
100	1		_aByrd, John C
245	0	0	_aPhase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. _h[electronic resource]
260			_bBlood _cJan 2010
300			_a489-95 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal _xadministration & dosage
650	0	4	_aAntibodies, Monoclonal, Murine-Derived
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aCyclophosphamide _xadministration & dosage
650	0	4	_aDisease-Free Survival
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Resistance, Neoplasm _xdrug effects
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLeukemia, Lymphocytic, Chronic, B-Cell _xblood
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aRecurrence
650	0	4	_aRituximab
650	0	4	_aVidarabine _xadministration & dosage
700	1		_aKipps, Thomas J
700	1		_aFlinn, Ian W
700	1		_aCastro, Januaro
700	1		_aLin, Thomas S
700	1		_aWierda, William
700	1		_aHeerema, Nyla
700	1		_aWoodworth, James
700	1		_aHughes, Steve
700	1		_aTangri, Shabnam
700	1		_aHarris, Sarah
700	1		_aWynne, Dee
700	1		_aMolina, Arturo
700	1		_aLeigh, Bryan
700	1		_aO'Brien, Susan
773	0		_tBlood _gvol. 115 _gno. 3 _gp. 489-95
856	4	0	_uhttps://doi.org/10.1182/blood-2009-08-237727 _zAvailable from publisher's website
999			_c19235568 _d19235568